The Effects of Thromboxane Antagonism on the Transit Time of Platelets Through the Spleen

A M Peters; I F Lane; M Sinclair; J T C Irwin; C N McCollum

doi:10.1055/s-0038-1657881

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1985; 54(02): 495-497
DOI: 10.1055/s-0038-1657881

Original Article

Schattauer GmbH Stuttgart

The Effects of Thromboxane Antagonism on the Transit Time of Platelets Through the Spleen

A M Peters

³Glaxo Group Research Ltd, Ware, UK

,

I F Lane

¹The Department of Surgery, Charing Cross Hospital, London

,

M Sinclair

²The Department Nuclear Medicine, Charing Cross Hospital, London

,

J T C Irwin

¹The Department of Surgery, Charing Cross Hospital, London

,

C N McCollum

¹The Department of Surgery, Charing Cross Hospital, London

› Author Affiliations

Abstract

PDF Download

Summary

The spleen is well-known as a site for platelet pooling, although the mechanisms controlling intrasplenic platelet transit are essentially unknown. We tested the possibility that thromboxane A₂ might be involved in this control by measuring intrasplenic platelet transit time in 10 subjects receiving a specific thromboxane A₂ receptor antagonist (AH23848B; 70 mg; Glaxo Group Research Ltd), in 10 receiving aspirin (300 mg) plus dipyridamole (75 mg), and in 9 receiving placebo. All doses were administered 3 times daily commencing 4 days prior to transit time measurement.

Mean intrasplenic platelet transit time was measured by monitoring the kinetics of equilibration of ¹¹¹In radiolabelled platelets between blood and spleen following intravenous injection. There was no difference between the mean transit time in the 3 groups of subjects, lending no support to the hypothesis that thromboxane A₂ is involved in the control of platelet traffic through the spleen.

Keywords

Thromboxane - Spleen platelets - ¹¹¹Indium

PDF (587 kb)

References

References
1 Aster RH. Pooling of platelets in the spleen: Role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 1966; 45: 645-657
2 Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1966; 48: 963-974
3 Heyns du PA, Lotter MG, Badenhorst PN, Van Reenen OR, Pieters H, Minaar PC, Retief FP. Kinetics, distribution and sites of destruction of inIn-labelled human platelets. Br J Haematol 1980; 44: 269-280
4 Peters AM, Klonizakis I, Lavender JP, Lewis SM. Use of ¹¹¹Indium labelled platelets to measure spleen function. Br J Haematol 1980; 46: 587-593
5 Aster RH. Studies of the mechanisms of “hypersplenic” thrombocytopenia in rats. J Lab Clin Med 1967; 70: 736-751
6 Harker LA. The role of the spleen in thrombokinetics. J Lab Clin Med 1971; 77: 247-253
7 Peters AM, Walport MJ, Bell RN, Lavender JP. Methods of measuring splenic blood flow and platelet transit time with ¹¹¹Inlabelled platelets. J Nucl Med 1984; 25: 86-90
8 Peters AM, Lavender JP. Platelet kinetics with indium-111 platelets: comparison with chromium-51 platelets. Sem Thromb Hemost 1983; 9: 100-114
9 Peters AM, Saverymuttu SH, Wonke B, Lewis SM, Lavender JP. The interpretation of platelet kinetic studies for the identification of sites of abnormal platelet destruction. Br J Haematol 1984; 57: 637-649
10 Peters AM, Lavender JP. Factors controlling the intrasplenic transit of platelets. Eur J Clin Invest 1982; 57: 191-195
11 Peters AM. Platelet kinetics and imaging in the spleen and hypersplenism. In: Platelet kinetics and imaging. Heyns du PA, Badenhorst PN, Lotter MG. (Ed.) CRC Press, Inc; Florida USA: (in press).
12 Vane JR. Prostacyclin: a hormone with a therapeutic potential. J Endocrinol 1982; 95: 3P-43P
13 Peters AM, Saverymuttu SH, Keshavarzian A, Bell RN, Lavender JP. Splenic pooling of granulocytes. Clin Sci 1985; 68: 283-289
14 Saverymuttu SH, Peters AM, Danpure HJ, Reavy HJ, Osman S, Lavender JP. Lung transit of ¹¹¹Indium-granulocytes. Relationship to labelling techniques. Scand J Haematol 1983; 30: 151-160
15 Martin BA, Dahlby R, Nicholls I, Hogg JC. Platelet sequestration in the lung with hemorrhagic shock and re-injection in dogs. J Appl Physiol 1981; 50: 1306-1312
16 Lane IF, Irwin JTC, Jennings SA, Poskitt KR, Greenhalgh RM, McCollum CN. A specific thromboxane A₂ antagonist evaluated in vascular graft patients. Br J Surg 1984; 71: 903
17 Brittain RT, Boutal L, Carter MC, Coleman RA, Collington EW, Geisow HP, Hallett P, Hornby EJ, Humphrey PPA, Jack D, Kennedy I, Lumley P, McCabe PJ, Skidmore IF, Thomas M, Wallis CJ. AH23848: A thromboxane receptor blocking drug which can clarify the pathophysiological role of thromboxane A₂ Circulation. (Suppl) (in press).
18 Brittain RT, Coleman RA, Collington EW, Hallett P, Humphrey PPA, Kennedy I, Lumley P, Sheldrick RLG, Wallis CJ. AH23848B: a potent selective thromboxane receptor blocking drug. Br J Pharmacol 1984; 83: 377P
19 Humphrey PPA, Lumley P. The effects of AH23848B, a novel thromboxane receptor blocking drug, on platelets and vascular smooth muscle. Br J Pharmacol 1984; 83: 378 P
20 Hawker RJ, Hawker LM, Wilkinson AR. Indium (¹¹¹In)-labelled human platelets: optimal method. Clin Sci 1980; 58: 243-248
21 Coleman RA, Humphrey PPA, Kennedy I, Leavy GP, Lumley P. Comparison of the actions of U46619, a prostaglandin H₂ analogue, with those of prostaglandin H₂ and thromboxane A₂ on some isolated smooth muscle preparations. Br J Pharmacol 1981; 73: 773-778
22 Lumley P, Humphrey PPA. A method for quantitating aggregation and analysing drug-receptor interactions on platelets in whole blood in-vitro . J Pharmacol Meth 1981; 6: 153-166
23 Blendis LM, Banks DC, Ramboer C, Williams R. Spleen blood flow and splanchnic haemodynamics in blood dyscrasia and other splenomegalies. Clin Sci 1970; 38: 73-84
24 Weiss L. A scanning electron microscopic study of the spleen. Blood 1974; 43: 665-691